Zonisamide

Generic Name
Zonisamide
Brand Names
Zonegran, Zonisade, Zonisamide Mylan
Drug Type
Small Molecule
Chemical Formula
C8H8N2O3S
CAS Number
68291-97-4
Unique Ingredient Identifier
459384H98V
Background

Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures. Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This latter action may inhibit the uptake of the inhibitory...

Indication

Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Zonisamide oral suspension is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.

Associated Conditions
Partial-Onset Seizures
Associated Therapies
-
Clinical Trials
Related News

Zonisamide for Weight Reduction in Obese Adults

Not Applicable
Completed
Conditions
Obesity
Interventions
Drug: Zonisamide
First Posted Date
2006-01-12
Last Posted Date
2017-01-12
Lead Sponsor
Duke University
Target Recruit Count
225
Registration Number
NCT00275834
Locations
🇺🇸

Duke University Medical Centre, Durham, North Carolina, United States

Zonisamide for Fibromyalgia & Migraine

Phase 4
Withdrawn
Conditions
Fibromyalgia
Migraine
First Posted Date
2005-11-29
Last Posted Date
2011-06-01
Lead Sponsor
University of Pittsburgh
Registration Number
NCT00259636
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

A Safety/Efficacy Trial of Zonisamide for Essential Tremor

Phase 2
Completed
Conditions
Essential Tremor
Interventions
Drug: Zonisamide
First Posted Date
2005-09-22
Last Posted Date
2012-06-22
Lead Sponsor
VA Greater Los Angeles Healthcare System
Target Recruit Count
25
Registration Number
NCT00223743
Locations
🇺🇸

VA Greater Los Angeles, Los Angeles, California, United States

A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies

Phase 4
Completed
Conditions
Epilepsy
Interventions
Drug: Zonisamide
Drug: Topiramate
First Posted Date
2005-09-12
Last Posted Date
2009-09-02
Lead Sponsor
Eisai Korea Inc.
Target Recruit Count
140
Registration Number
NCT00154076
Locations
🇰🇷

Daegu Catholic University Medical Center, Daegu, Korea, Republic of

Dose Response Study of Zonegran in Patients With Newly Diagnosed Epilepsy

Phase 3
Completed
Conditions
Epilepsy, Complex Partial
First Posted Date
2003-03-19
Last Posted Date
2011-07-18
Lead Sponsor
Eisai Inc.
Target Recruit Count
165
Registration Number
NCT00056576
Locations
🇺🇸

Suncoast Neuroscience Associates, Inc., St. Petersburg, Florida, United States

🇺🇸

AMO Corporation, Tallahassee, Florida, United States

🇺🇸

Florida Epilepsy & Seizure Disorder Center, PA, Tampa, Florida, United States

and more 32 locations

A Study to Measure the Safety and Effectiveness of Zonisamide in Subjects With Migraine Headache

Phase 2
Completed
Conditions
Migraine Headache
First Posted Date
2003-03-05
Last Posted Date
2015-12-14
Lead Sponsor
Elan Pharmaceuticals
Target Recruit Count
204
Registration Number
NCT00055484
Locations
🇺🇸

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

🇺🇸

University of South Alabama Medical Ctr Department of Neurology, Mobile, Alabama, United States

🇺🇸

The New England Center for Headache, Stamford, Connecticut, United States

and more 9 locations

Open-label Adjunctive Zonisamide for Bipolar Disorder

Phase 4
Terminated
Conditions
Bipolar Disorders
First Posted Date
2002-10-10
Last Posted Date
2015-12-14
Lead Sponsor
Elan Pharmaceuticals
Target Recruit Count
20
Registration Number
NCT00047567
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy